Abstract
ObjectivePeople with schizophrenia are at increased risk of metabolic syndrome (MetS), contributing to excess morbidity and mortality. This study examined MetS monitoring rates and prevalence in people with schizophrenia receiving public mental health care in Queensland.MethodsData from the Consumer Integrated Mental Health and Addiction Application (CIMHA) were extracted for individuals aged 18-64 with a schizophrenia diagnosis. MetS was determined using International Diabetes Federation criteria.ResultsOf 5802 individuals, 16.0% had sufficient data to determine MetS status. Among those with complete data, MetS prevalence was 53.2%. MetS was significantly more common in regional than metropolitan areas. Blood pressure and BMI were recorded for most patients (≥74%), but biochemical indices (fasting glucose, HDL, triglycerides) were recorded in only 26.4%-35.5%.ConclusionsMetS is highly prevalent in schizophrenia, yet routine monitoring is incomplete, particularly for biochemical markers. Strengthening data integration across healthcare systems and ensuring access to evidence-based interventions for MetS management, particularly in regional areas, is critical to addressing this major health disparity.